Health AI Central
Share:
Peer-Reviewed Publication
BJUI Compass2026;7(8):e70274.August 1, 2026Journal Article

The impact of ERBB2 alterations in muscle-invasive bladder cancer after neoadjuvant chemotherapy.

Earle F Burgess1, Hilary Elom1, Landon C Brown1, Michael McCormack2, Ericson Stoen2, Metamia Ciampricotti3, Edward Williams3, James T Symanowski1
1Atrium Health Wake Forest Baptist Comprehensive Cancer Center Charlotte North Carolina USA.
2Atrium Health Wake Forest Baptist Comprehensive Cancer Center Winston-Salem North Carolina USA.
3Tempus AI, Inc. Chicago Illinois USA.
PubMed PMC DOI PDF

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.